威廉·卡森购入了 4,115 股 Annexon（NASDAQ:ANNX）的股票
William Carson, Director of Annexon, Inc. (NASDAQ:ANNX), purchased 4,115 shares at $3.17 each on October 30, totaling $13,044.55. This acquisition increased his holdings to 46,175 shares, valued at approximately $146,374.75, marking a 9.78% rise in his position. Following the transaction, Annexon stock rose by 7.8% to $3.16. The company has a market cap of $347.24 million and a consensus rating of "Hold" from analysts, with a price target of $12.50.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson purchased 4,115 shares of the stock in a transaction on Thursday, October 30th. The shares were purchased at an average cost of $3.17 per share, for a total transaction of $13,044.55. Following the acquisition, the director directly owned 46,175 shares of the company's stock, valued at approximately $146,374.75. This represents a 9.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Annexon Stock Up 7.8%
NASDAQ:ANNX traded up $0.23 during trading hours on Friday, hitting $3.16. 3,658,058 shares of the stock traded hands, compared to its average volume of 1,659,900. Annexon, Inc. has a 1 year low of $1.28 and a 1 year high of $7.63. The company has a market cap of $347.24 million, a price-to-earnings ratio of -2.45 and a beta of 1.36. The stock has a 50 day moving average price of $2.77 and a 200 day moving average price of $2.42.
Annexon (NASDAQ:ANNX - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.02. Equities analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Nuveen LLC bought a new position in Annexon during the 1st quarter worth about $670,000. J. Safra Sarasin Holding AG grew its holdings in Annexon by 49.9% during the 2nd quarter. J. Safra Sarasin Holding AG now owns 381,441 shares of the company's stock worth $915,000 after acquiring an additional 126,903 shares in the last quarter. Wellington Management Group LLP grew its holdings in Annexon by 32.9% during the 1st quarter. Wellington Management Group LLP now owns 356,480 shares of the company's stock worth $688,000 after acquiring an additional 88,314 shares in the last quarter. XTX Topco Ltd grew its holdings in Annexon by 65.4% during the 1st quarter. XTX Topco Ltd now owns 58,130 shares of the company's stock worth $112,000 after acquiring an additional 22,979 shares in the last quarter. Finally, Matauro LLC bought a new position in Annexon during the 2nd quarter worth about $27,000.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on ANNX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Annexon in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of Annexon in a research note on Friday, August 15th. Finally, Zacks Research raised shares of Annexon from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Annexon presently has a consensus rating of "Hold" and an average price target of $12.50.
Get Our Latest Stock Analysis on ANNX
Annexon Company Profile
(Get Free Report)Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Read More
- Five stocks we like better than Annexon
- What is a Dividend King?
- Why VGT May Be a Smarter Bet Than Chasing Individual Tech Stocks
- How to Calculate Stock Profit
- Equinix Stock Rises Despite Lower Revenue Guidance
- The 3 Best Fintech Stocks to Buy Now
- MongoDB: It’s No Trick, This AI Play Is a Treat
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Annexon Right Now?
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
